Related Experiment Videos
[Allogenic bone marrow transplantation: report of 3 cases in Chile]
Insights
Three patients underwent successful allogeneic bone marrow transplants in Chile for leukemia and aplastic anemia. This complex therapy offers a chance for patients with poor prognoses on conventional treatments.
Area of Science:
- Hematology
- Transplant Immunology
Background:
- Allogeneic bone marrow transplantation (BMT) is a critical treatment for hematologic malignancies and severe aplastic anemia.
- HLA-identical sibling transplants offer a potential curative option for patients refractory to standard therapies.
Observation:
- Three patients (28F, 32M, 18M) received BMT for acute non-lymphatic leukemia (n=2) and severe aplastic anemia (n=1).
- Conditioning involved Busulfan and Cyclophosphamide, with GVHD prophylaxis using cyclosporine and steroids.
- Patients experienced fever, requiring broad-spectrum antibiotics and amphotericin (case 3).
Findings:
- Disease-free survival exceeded 232, 50, and 201 days post-transplant.
- Hematological reconstitution occurred within 10-13 days.
- Acute and chronic graft-versus-host disease (GVHD) were observed and managed with escalated immunosuppression.
Implications:
- Successful allogeneic BMT in Chile demonstrates the feasibility of this advanced therapy in a new setting.
- This approach provides a viable treatment option for select patients with poor outcomes on conventional therapies.
- Further research can optimize protocols and expand access to allogeneic BMT.
Abstract:
Three patients, a 28 years old female (case 1), and two males aged 32 and 18 (cases 2 and 3) received allogeneic bone marrow transplants for acute non lymphatic leukemia (cases 1 and 2) and severe aplastic anemia (case 3) from HLA identical siblings. All patients were conditioned with Busulfan and Cyclophosphamide, and received GVHD prophylaxis with cyclosporin and steroids. Disease free survival is greater than 232, greater than 50 and greater than 201 days. Hematological reconstitution was detected 12, 13 and 10 days post transplant. All patients presented fever during the first month and received broad spectrum antibiotics including amphotericin in case 3. Acute GVHD presented in case 3 and chronic GVDH in case 1. Both patients responded to higher doses of cyclosporine and steroids. Allogeneic bone marrow transplant is a complex and expensive therapy, but can benefit a selected group of patients who fare poorly with conventional therapy. This report communicates the first three successful allogeneic bone marrow transplants performed in Chile.